Interní Med. 2015; 17(5): 247-251

Single pill combination of linagliptin and metformin - case report

MUDr.Jarmila Jirkovská
Univerzita Karlova v Praze, 1. lékařská fakulta, Interní klinika 1. LF UK a ÚVN Praha, Diabetologické centrum

The case report presents the treatment of patient in working age with type 2 diabetes mellitus with modern antidiabetic therapy of single

pill combination of linagliptin and metformin. This therapy resulted in massive decrease of glycated hemoglobin without hypoglycemic

events. Single pill combination of linagliptin and metformin was chosen because of better compliance of patients on single pill combination

and added benefit of linagliptin molecule in this single pill combination.

Keywords: linagliptin, type 2 diabetes mellitus, single pill combination

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirkovská J. Single pill combination of linagliptin and metformin - case report. Interní Med. 2015;17(5):247-251.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Doporučený postup péče o diabetes mellitus 2. typu. Dostupný online na: http://www.diab.cz/dokumenty/dm2_12.pdf. Citováno 4. 11. 2015.
    2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140-149. Go to original source... Go to PubMed...
    3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2015 Sep 17. [Epub ahead of print]. Go to original source... Go to PubMed...
    4. Ross S, Caballero E, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle H-J, von Eynatten M. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes with marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Diabetes Obes Metab. 2015; 17: 136-144. Go to original source... Go to PubMed...
    5. von Eynatten M, Hehnke U, Cooper ME, Perkovic V, Rosenstock J, Wanner C, Woerle H-J. Renal safety and outcomes with linagliptin: meta-analysis of individual data for 5466 patients with type 2 diabetes. Diabetologia. 2013; 56(Suppl1): S364.
    6. SPC Trajenta. Dostupné na www.sukl.cz. Citováno 4. 11. 2015.
    7. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012; 13: 3. Go to original source... Go to PubMed...
    8. Doporučené postupy pro diagnostiku a léčbu diabetické retinopatie. Dostupné online na: http://www.diab.cz/dokumenty/standard_oci.pdf. Citováno 4. 11. 2015.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.